Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program.

Steidle C, Padma-Nathan H, Salem S, Tayse N, Thwing D, Fendl J, Yeager J, Harning R.

Urology. 2002 Dec;60(6):1077-82.

PMID:
12475674
2.
3.
4.

Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.

Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A.

BJU Int. 2004 Oct;94(6):871-7.

5.

Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.

Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, Kopernicky V.

Eur Urol. 2004 Sep;46(3):362-9; discussion 369.

PMID:
15306109
6.

[Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction].

Jiang H, Xu QQ, Hong K, Wang XF, Zhu JC.

Zhonghua Nan Ke Xue. 2003 Apr;9(2):97-9. Chinese.

PMID:
12749125
8.
9.

Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.

Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama à Nijeholt GA, Lynch SF, Morgan RJ, Müller SC, Porst H, Pryor JP, Ryan P, Witzsch UK, Hall MM, Place VA, Spivack AP, Gesundheit N.

Br J Urol. 1998 Jun;81(6):889-94.

PMID:
9666777
11.

Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea.

Kim SC, Ahn TY, Choi HK, Choi NG, Chung TG, Chung WS, Hwang TK, Hyun JS, Jung GW, Kim CI, Kim JJ, Kim SW, Lee CH, Lee KS, Lee WH, Min KS, Moon KH, Paic JS, Park KS, Park NC, Park YK, Seo JK, Seo KK, Shin JS, Yoon YR, Lee WC.

Int J Impot Res. 2000 Apr;12(2):97-101.

PMID:
11052635
12.

Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.

Nagao K, Kimoto Y, Marumo K, Tsujimura A, Vail GM, Watts S, Ishii N, Kamidono S.

Urology. 2006 Oct;68(4):845-51.

PMID:
17070365
13.

Optimizing the therapeutic approach of transurethral alprostadil.

Ekman P, Sjögren L, Englund G, Persson BE.

BJU Int. 2000 Jul;86(1):68-74.

14.

Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.

Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C; Trial Evaluating the Activity of Tadalafil for Erectile Dysfunction-United States (TREATED-US) Study Group.

Urology. 2005 Feb;65(2):353-9.

PMID:
15708052
15.
16.

Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men.

Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A.

Int J Impot Res. 2001 Dec;13(6):317-21.

PMID:
11918246
17.

A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil.

Hellstrom WJ, Bennett AH, Gesundheit N, Kaiser FE, Lue TF, Padma-Nathan H, Peterson CA, Tam PY, Todd LK, Varady JC, Place VA.

Urology. 1996 Dec;48(6):851-6.

PMID:
8973666
18.
19.
20.

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial.

Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdock M, Wilkins HJ, McBride TA, Colopy MW; Patient Response with Vardenafil in Slidenafil Non-Responders (PROVEN) Study Group.

BJU Int. 2004 Dec;94(9):1301-9. Erratum in: BJU Int. 2005 Aug;96(3):466.

Items per page

Supplemental Content

Write to the Help Desk